IP Library Granted Patent US 9,701,706
Granted Patent B2
US 9,701,706 · App. 15/358,938 · Granted Jul 11, 2017

Pyrrolopyrimidine nucleosides and analogs thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,701,706
App. No.
15/358,938
Granted
Jul 11, 2017
Kind
B2
Abstract

The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein R c and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.

Claims (59)

1. A compound of Formula II:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof, wherein:

Y is —C(O)—, or

wherein X 1 is independently O, NH, or S, X 2 is independently a bond, —O—, —S—, or —NH—, and X 3 is independently —OR, —NHR II , or —SR II ;

each R is independently —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo, R 1 , —OR 1 , —NR 1 R 2 , —SR 1 , —OC(O)R 1 , —C(O)OR 1 , —NHC(O)OR 1 , or —NHC(O)R 1 ;

R a and R b are each independently, at each occurrence, —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo —OR 1 , —NR 1 R 2 , —SR 1 , —OC(O)R 1 , —C(O)OR 1 —NHC(O)OR 1 , or —NHC(O)R 1 ;

R 1 and R 2 are each independently, at each occurrence, —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo, —R 3 , —R 4 , —OR 3 , —NR 3 R 4 , —SR 3 , —OC(O)R 3 , —C(O)OR 3 , —NHC(O)OR 3 , or —NHC(O)R 3 ;

R 3 and R 4 are each independently, at each occurrence, —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo, aryl, heteroaryl, —OH, —NH 2 , —SH, —OC(O)H, —C(O)OH, —NHC(O)OH, or —NHC(O)H;

R c is independently —H or -D; and

n is independently 0, 1, 2 or 3.

2. The compound of claim 1 , wherein R a is —H.

3. The compound of claim 1 , wherein R b is —H.

4. The compound of claim 1 , wherein R c is —H.

5. The compound of claim 1 , wherein n is 0.

6. The compound of claim 1 , wherein R a , R b and R c are —H.

7. The compound of claim 1 , wherein R a , R b and R c are —H and n is 0.

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

9. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

10. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

11. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

12. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

13. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

14. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

15. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

16. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

17. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

18. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

19. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

20. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

21. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

22. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

23. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

24. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

25. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

26. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof, and a pharmaceutically acceptable carrier.

27. The pharmaceutical composition of claim 26 , wherein the compound is:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof, and a pharmaceutically acceptable carrier.

28. A method of treating a viral infection or a viral-infection associated disease or disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

29. A method of treating a viral infection or a viral-infection associated disease or disorder comprising administering to a subject in need thereof an effective amount of the compound:

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.

30. The method of claim 29 wherein the viral infection is norovirus.

Assignments (4)
SECURITY AGREEMENT Recorded Sep 4, 2025
From: CHIMERIX, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 072802/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: BOUGHER, JOHN HENRY, III; CHANGALVALA, RAMAMURTY V S; LANIER, ERNEST RANDALL, JR.; MCIVER, ANDREW LOUIS; ROBERTSON, BRADLEY DAVID; SELLESETH, DEAN WALLACE; SETHNA, PHIROZE BEHRAM; WARE, ROY W.
To: CHIMERIX INC.
Reel/Frame 042254/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2017
From: WARE, ROY WENDELL
To: CHIMERIX INC.
Reel/Frame 041508/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2017
From: TOWNSEND, LEROY; DRACH, JOHN
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 041913/0207 →